Cardiovascular Drugs Practice Questions

Q: What are the most potent drugs for reducing plasma cholesterol levels?

Statins. **Statins (HMG-CoA Reductase Inhibitors)** are the most potent drugs for lowering LDL-cholesterol [2]. They work by competitively inhibiting the rate-limiting enzyme in cholesterol synthesis, HMG-CoA reductase [1, 2]. This reduction in intracellular cholesterol triggers a compensatory **upregulation of LDL receptors** on hepatocytes, leading to increased clearance of LDL from the plasma. Statins can reduce LDL levels by 20% to over 60%, depending on the dose and potency (e.g., Atorvastatin, Rosuvastatin) [2]. **Why other options are incorrect:** * **Plant sterols:** These compete with cholesterol for micellar solubilization in the intestine. While they reduce absorption, their efficacy is modest (approx. 10% reduction) compared to statins. * **Fibrates (e.g., Fenofibrate):** These are agonists of **PPAR-α**. Their primary role is reducing **triglycerides** and increasing HDL; they have a variable and much weaker effect on LDL-C. * **Anion exchange resins (e.g., Cholestyramine):** These sequester bile acids in the gut. While effective, they are less potent than statins and often cause GI side effects, limiting their clinical utility as first-line monotherapy. **High-Yield NEET-PG Pearls:** * **Pleiotropic effects:** Statins provide cardiovascular benefits beyond lipid lowering, such as plaque stabilization and anti-inflammatory effects [2]. * **Side effects:** Monitor for **myopathy/rhabdomyolysis** (increased risk when combined with fibrates) and hepatotoxicity [2]. * **Timing:** Most statins are given at bedtime because hepatic cholesterol synthesis peaks at night (except Atorvastatin and Rosuvastatin, which have long half-lives). * **Newer agents:** PCSK9 inhibitors (e.g., Evolocumab) are now considered more potent than statins but were not listed in the options.

Q: Which of the following drugs is commonly associated with causing a cough?

Lisinopril. **Explanation:** **Lisinopril** is an **ACE (Angiotensin-Converting Enzyme) inhibitor**. The dry, hacking cough associated with this class of drugs occurs in approximately 5–20% of patients. * **Mechanism:** ACE is identical to Kininase II, the enzyme responsible for the degradation of **bradykinin** and **Substance P**. When ACE is inhibited, these inflammatory autacoids accumulate in the upper respiratory tract and lungs. Bradykinin sensitizes sensory nerve endings, leading to the characteristic dry cough. **Analysis of Incorrect Options:** * **B. Propranolol:** A non-selective beta-blocker. While it can cause **bronchospasm** (especially in asthmatics) by blocking $\beta_2$ receptors, it does not typically cause a dry cough. * **C. Verapamil:** A non-dihydropyridine Calcium Channel Blocker (CCB). Its most characteristic side effect is **constipation** and peripheral edema, not cough. * **D. Sodium nitroprusside:** A potent vasodilator used in hypertensive emergencies. Its major toxicity is related to **cyanide and thiocyanate accumulation**, leading to metabolic acidosis and psychosis. **NEET-PG High-Yield Pearls:** 1. **Management:** If a patient develops an ACEI-induced cough, the drug should be discontinued and switched to an **ARB (Angiotensin Receptor Blocker)** like Losartan, as ARBs do not affect bradykinin levels. 2. **Gender Predilection:** The cough is more common in **females** and patients of Chinese descent. 3. **Other ACEI Side Effects:** Remember the mnemonic **CAPTOPRIL** (Cough, Angioedema, Proteinuria/Potassium excess, Taste changes, Orthostatic hypotension, Pregnancy contraindication, Renal artery stenosis contraindication, Increased renin, Leukopenia).

Q: A patient on antihypertensive medication develops a dry cough. Which of the following drugs might be responsible for this condition?

ACE inhibitors. **Explanation:** **Correct Option: B. ACE inhibitors** ACE inhibitors (e.g., Enalapril, Lisinopril) are the most common cause of drug-induced dry cough, occurring in 5–20% of patients. The underlying mechanism involves the inhibition of **Angiotensin-Converting Enzyme (ACE)**, which is also responsible for the degradation of **Bradykinin** and **Substance P**. When ACE is inhibited, these inflammatory peptides accumulate in the upper respiratory tract and lungs, sensitizing sensory nerve endings and triggering a persistent, non-productive cough. **Incorrect Options:** * **A. Diuretics:** Common side effects include electrolyte imbalances (hypokalemia) and hyperuricemia, but they do not affect the kinin system or cause a cough. * **C. Calcium Channel Blockers (CCBs):** These typically cause peripheral edema (Amlodipine), headache, or constipation (Verapamil), but not respiratory symptoms. * **D. Beta-blockers:** While non-selective beta-blockers (e.g., Propranolol) can cause **bronchospasm** or wheezing in asthmatics due to $\beta_2$ blockade, they do not cause a dry cough in the general hypertensive population. **High-Yield Clinical Pearls for NEET-PG:** * **Management:** If a patient develops an ACEI-induced cough, the drug should be stopped. The cough usually resolves within 1–4 weeks. * **Alternative:** **Angiotensin Receptor Blockers (ARBs)** like Losartan are the preferred alternative because they do not affect ACE or bradykinin levels. * **Other Side Effects of ACEIs:** Remember the mnemonic **CAPTOPRIL**: **C**ough, **A**ngioedema, **P**roteinuria, **T**aste changes, **O**rthostatic hypotension, **P**regnancy contraindication (Teratogenic), **R**enal artery stenosis contraindication, **I**ncreased potassium (Hyperkalemia), **L**eukopenia.

Q: A patient with hypertension, tachycardia and early renal involvement is prescribed an ARB (telmisartan). What is the most likely mechanism by which the drug helps improve heart rate and blood pressure?

By decreasing peripheral vascular resistance. ***By decreasing peripheral vascular resistance*** - ARBs (Angiotensin Receptor Blockers) like **telmisartan** selectively block AT1 receptors, preventing angiotensin II from binding - This blockade leads to **vasodilation** (reduced vasoconstriction) → decreased peripheral vascular resistance (afterload reduction) - Lower afterload reduces **blood pressure** and decreases cardiac workload, which secondarily **improves heart rate** - ARBs also provide **renoprotection** by reducing intraglomerular pressure, making them ideal for hypertension with early renal involvement *By decreasing cardiac output directly* - ARBs do not have direct negative inotropic effects on the heart - Any reduction in cardiac output is secondary to decreased afterload, not a primary mechanism *By directly blocking beta-1 receptors* - This describes the mechanism of **beta-blockers** (e.g., metoprolol, atenolol), not ARBs - Beta-blockers directly reduce heart rate and contractility; ARBs work via peripheral vasodilation *By increasing sodium excretion via loop diuretics* - This describes the mechanism of **loop diuretics** (e.g., furosemide), not ARBs - While ARBs may have mild diuretic effects, their primary mechanism is reducing peripheral vascular resistance through AT1 receptor blockade

Q: A patient with a history of hypertension is given the drug 'X'. Identify 'X'?

Aliskiren. ***Aliskiren*** - Aliskiren is a **direct renin inhibitor**. The diagram shows that drug 'X' directly inhibits the release or action of **renin** from the kidneys. - By inhibiting renin, it blocks the first and rate-limiting step of the **Renin-Angiotensin-Aldosterone System (RAAS)**, preventing the conversion of **angiotensinogen** to **angiotensin I**. *Captopril* - Captopril is an **Angiotensin-Converting Enzyme (ACE) inhibitor**. It acts later in the pathway to block the conversion of **angiotensin I** to **angiotensin II**. - This mechanism is different from drug 'X', which acts on **renin** at the beginning of the cascade. *Spironolactone* - Spironolactone is an **aldosterone antagonist** and a potassium-sparing diuretic. It acts at the end of the RAAS pathway. - It works by blocking **aldosterone receptors** in the distal tubules of the kidney, preventing sodium and water reabsorption, which is downstream from the action of renin. *Losartan* - Losartan is an **Angiotensin II Receptor Blocker (ARB)**. It prevents **angiotensin II** from binding to its receptors on blood vessels and the adrenal glands. - This action occurs much later in the pathway compared to the direct inhibition of **renin** shown by drug 'X'.

Q: Which of these drugs stimulates PPAR-alpha (Peroxisome proliferator-activated receptor alpha)?

Gemfibrozil. ***Gemfibrozil***- It belongs to the **fibrate class** of lipid-lowering drugs, and its primary mechanism is activating the **Peroxisome Proliferator-Activated Receptor alpha (PPAR-alpha)**.- PPAR-alpha activation leads to increased synthesis of **lipoprotein lipase (LPL)**, enhancing the catabolism of **VLDL** and chylomicrons, which effectively lowers **triglyceride** levels.*Ezetimibe*- This drug selectively inhibits the absorption of dietary and biliary cholesterol by blocking the **NPC1L1 (Niemann-Pick C1-Like 1)** transporter protein located on the brush border of the small intestine enterocytes.- It does not interact with PPAR-alpha but is typically used to reduce **LDL cholesterol**, often in combination with statins.*Colestipol*- It is a **bile acid sequestrant** (resin) that binds negatively charged bile acids in the intestinal lumen, forming a non-absorbable complex that is excreted in stool.- The loss of bile acids forces the liver to increase the synthesis of new bile acids from cholesterol, thereby upregulating hepatic **LDL receptors** and reducing plasma LDL levels.*Simvastatin*- This drug is an HMG-CoA reductase inhibitor (**statin**), which is the rate-limiting enzyme in hepatic cholesterol synthesis.- By reducing intracellular cholesterol synthesis, it causes upregulation of surface **LDL receptors** on hepatocytes, increasing LDL clearance from the blood.

Q: A patient with atrial fibrillation is started on a medication that prolongs the QT interval by blocking potassium channels. Which of the following is the most likely adverse effect of this antiarrhythmic drug?

Torsades de pointes. ***Torsades de pointes*** - Prolongation of the **QT interval**, often secondary to **potassium channel blockade** (Class III antiarrhythmics), is the major risk factor for developing **Torsades de pointes (TdP)**, a polymorphic ventricular tachycardia. - TdP is related to early afterdepolarizations (EADs) that occur during the prolonged repolarization phase (QT prolongation) of the ventricular action potential. *Bradycardia* - While some antiarrhythmics like beta-blockers (Class II) or calcium channel blockers (Class IV) can cause bradycardia, direct potassium channel blockers (Class III) primarily impact repolarization, not heart rate initiation or conduction velocity. - Bradycardia is more commonly associated with drugs that decrease automaticity (e.g., **Amiodarone** has mixed effects, but its beta-blocking action can cause bradycardia). *Hypotension* - Hypotension can be a side effect of rapidly infused antiarrhythmics or those with significant peripheral vasodilatory effects (e.g., **Amiodarone** or Class I agents), but it is not the classic, unique cardiotoxic adverse effect linked specifically to QT prolongation. - This adverse effect is related to systemic pharmacodynamics rather than the electrophysiological mechanism of potassium channel blockade. *Atrial flutter* - Atrial flutter is a regular, rapid atrial rhythm (often 250-350 bpm) that can occur as a primary disease or sometimes transition from atrial fibrillation, but it is typically not a direct, life-threatening adverse effect cause by potassium channel blocking that prolongs QT interval. - Antiarrhythmic therapy (especially Class I and III agents) can rarely turn pre-existing **atrial fibrillation** into slower, organized **atrial flutter** with 1:1 conduction, which is dangerous, but TdP remains the principal concern for QT-prolonging drugs.

Q: Which of the following is not true regarding bempedoic acid?

It non-competitively inhibits ATP citrate lyase. ***It non-competitively inhibits ATP citrate lyase*** - This statement is **incorrect** because Bempedoic acid's active metabolite, **ETC-1002-CoA**, inhibits **Adenosine Triphosphate Citrate Lyase (ACL)**, but it does so in a **competitive** manner, not a non-competitive one. - This inhibition leads to reduced acetyl-CoA production in the liver, subsequently lowering **cholesterol synthesis**. ***It is a dicarboxylic acid*** - This statement is **true**. Bempedoic acid (ETC-1002) is structurally a **dicarboxylic acid derivative**, requiring activation in the liver by short-chain acyl-CoA synthetase 1 (ACSVL1). - The presence of the dicarboxylic acid structure is key to its mechanism and selective liver activation. ***It is used when statins and diet cannot control dyslipidemia*** - This statement is **true**. Bempedoic acid is approved primarily for patients with **heterozygous familial hypercholesterolemia** or established **atherosclerotic cardiovascular disease (ASCVD)** who require additional lowering of LDL-C despite maximally tolerated statin therapy. - It is often used as an adjunct to diet and other lipid-lowering therapies, particularly in statin-intolerant patients. ***It inhibits de-novo synthesis of liver cholesterol*** - This statement is **true**. By competitively inhibiting **ATP Citrate Lyase (ACL)**, Bempedoic acid reduces the availability of **acetyl-CoA** in the cytosol, which is the necessary precursor for *de novo* cholesterol synthesis in the liver. - This mechanism is upstream of the HMG-CoA reductase step targeted by statins, offering a complementary path to reducing cholesterol.

Q: Mechanism of action of Fenoldopam drug is:

D1 agonist. ***D1 agonist*** - **Fenoldopam** is a selective, short-acting agonist of the **Dopamine-1 (D1) receptor**. - D1 receptor stimulation leads to **vasodilation** in peripheral, coronary, renal, and splanchnic arterial beds, explaining its use as a rapid-acting antihypertensive agent. ***Alpha-1 antagonist*** - Alpha-1 antagonists (e.g., prazosin, doxazosin) block peripheral vasoconstriction and are used for hypertension and BPH, which is not the mechanism of Fenoldopam. - These drugs act by blocking the binding of **norepinephrine** to the alpha-1 receptor on smooth muscle cells. ***Beta-2 agonist*** - Beta-2 agonists (e.g., salbutamol) primarily act as **bronchodilators** by relaxing bronchial smooth muscles, and are unrelated to Fenoldopam's mechanism of action. - They sometimes cause peripheral vasodilation and increased heart rate, but Fenoldopam acts via the D1 receptor. ***D2 antagonist*** - D2 antagonists (e.g., metoclopramide, typical antipsychotics) block dopamine receptors, resulting in antiemetic or antipsychotic effects. - This mechanism is opposite to that of Fenoldopam, which is a dopamine **receptor agonist**.

Q: The image above (labeled img-78.jpeg) shows a cardiac action potential. The phase marked X represents the funny current (If). Which drug selectively blocks this funny current and is used in chronic CHF and chronic stable angina?

Ivabradine. ***Ivabradine*** - **Ivabradine** is a specific and selective **funny current (If) inhibitor**, which reduces the heart rate without affecting myocardial contractility or repolarization. - It is approved for use in patients with **chronic heart failure** with reduced ejection fraction and normal sinus rhythm, and for **chronic stable angina** in patients intolerant or contraindicated to beta-blockers. *Digoxin* - **Digoxin** is a cardiac glycoside that increases **myocardial contractility** (positive inotropy) and slows heart rate by affecting the Na+/K+-ATPase pump and increasing vagal tone. - It is primarily used to treat **heart failure** with reduced ejection fraction and **atrial fibrillation**, but it does not directly block the funny current. *Verapamil* - **Verapamil** is a **non-dihydropyridine calcium channel blocker** that primarily acts on the heart, reducing heart rate and contractility and dilating coronary arteries. - While it can slow heart rate, its primary mechanism involves blocking L-type calcium channels, not directly inhibiting the funny current. *Adenosine* - **Adenosine** is an **endogenous nucleoside** that acts on A1 receptors in the AV node, causing transient AV block and restoring sinus rhythm in supraventricular tachycardias. - Its action is very short-lived and it is primarily used for the acute treatment of **paroxysmal supraventricular tachycardia (PSVT)**, not for chronic management of heart failure or angina through funny current inhibition.

Question 1

What are the most potent drugs for reducing plasma cholesterol levels?

Accepted Answer

Statins

Answer

Plant sterols

Answer

Fibrates

Answer

Anion exchange resins

Question 2

Which of the following drugs is commonly associated with causing a cough?

Accepted Answer

Lisinopril

Answer

Propranolol

Answer

Verapamil

Answer

Sodium nitroprusside

Question 3

A patient on antihypertensive medication develops a dry cough. Which of the following drugs might be responsible for this condition?

Accepted Answer

ACE inhibitors

Answer

Diuretics

Answer

Calcium channel blockers

Answer

Beta blockers

Question 4

A patient with hypertension, tachycardia and early renal involvement is prescribed an ARB (telmisartan). What is the most likely mechanism by which the drug helps improve heart rate and blood pressure?

Accepted Answer

By decreasing peripheral vascular resistance

Answer

By decreasing cardiac output directly

Answer

By directly blocking beta-1 receptors

Answer

By increasing sodium excretion via loop diuretics

Question 5

A patient with a history of hypertension is given the drug 'X'. Identify 'X'?

Accepted Answer

Aliskiren

Answer

Losartan

Answer

Spironolactone

Answer

Captopril

Question 6

Which of these drugs stimulates PPAR-alpha (Peroxisome proliferator-activated receptor alpha)?

Accepted Answer

Gemfibrozil

Answer

Ezetimibe

Answer

Colestipol

Answer

Simvastatin

Question 7

A patient with atrial fibrillation is started on a medication that prolongs the QT interval by blocking potassium channels. Which of the following is the most likely adverse effect of this antiarrhythmic drug?

Accepted Answer

Torsades de pointes

Answer

Hypotension

Answer

Bradycardia

Answer

Atrial flutter

Question 8

Which of the following is not true regarding bempedoic acid?

Accepted Answer

It non-competitively inhibits ATP citrate lyase

Answer

It is a dicarboxylic acid

Answer

It is used when statins and diet cannot control dyslipidemia

Answer

It inhibits de-novo synthesis of liver cholesterol

Question 9

Mechanism of action of Fenoldopam drug is:

Accepted Answer

D1 agonist

Answer

Beta-2 agonist

Answer

Alpha-1 antagonist

Answer

D2 antagonist

Question 10

The image above (labeled img-78.jpeg) shows a cardiac action potential. The phase marked X represents the funny current (If). Which drug selectively blocks this funny current and is used in chronic CHF and chronic stable angina?

Accepted Answer

Ivabradine

Answer

Digoxin

Answer

Verapamil

Answer

Adenosine

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?